This study is currently not recruiting participants.

PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY ARC004

Study on Investigational Treatment for Peanut Allergies

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to give subjects who received placebo in the last study (ARC003) the chance to receive AR101, the active study drug which contains peanut allergen in the form of peanut flour.

Detailed description of study

The purpose of this study is to give subjects who received placebo in the last study (ARC003) the chance to receive AR101, the active study drug which contains peanut allergen in the form of peanut flour.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: peanut allergy
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to give subjects who received placebo in the last study the chance to receive an investigational medication that contains peanut allergen in the form of peanut flour. This study investigates the effects of the investigational medication on individuals with peanut allergies.

Participants will receive the investigational medication, which is designed to help the body become less sensitive to peanuts. The investigational medication contains peanut flour, and participants will be monitored to see how their bodies respond to it.

  • Who can participate: Participants must meet specific eligibility criteria, including age range and health status, which will be provided by the study coordinators.
  • Study details: Participants will take the investigational treatment containing peanut flour to see how their bodies respond. The study aims to observe changes in peanut sensitivity. A placebo is an inactive substance designed to have no therapeutic effect, used as a control in testing new drugs.
Updated on 19 Feb 2024. Study ID: 1701741206

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team